CorMedix Inc.
CRMD
$6.30
$0.233.79%
| Weiss Ratings | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.68 | |||
| Price History | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -41.50% | |||
| 30-Day Total Return | -43.62% | |||
| 60-Day Total Return | -22.98% | |||
| 90-Day Total Return | -43.09% | |||
| Year to Date Total Return | -23.36% | |||
| 1-Year Total Return | 54.41% | |||
| 2-Year Total Return | 45.50% | |||
| 3-Year Total Return | 12.70% | |||
| 5-Year Total Return | 104.55% | |||
| 52-Week High % Change | -56.17% | |||
| 52-Week Low % Change | 68.14% | |||
| Price | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $13.85 | |||
| 52-Week Low Price | $3.61 | |||
| 52-Week Low Price (Date) | Aug 13, 2024 | |||
| 52-Week High Price (Date) | Oct 29, 2024 | |||
| Valuation | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 395.65M | |||
| Enterprise Value | 344.48M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.33 | |||
| Earnings Per Share Growth | -64.53% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 8.59 | |||
| Price/Book (Q) | 4.62 | |||
| Enterprise Value/Revenue (TTM) | 7.92 | |||
| Price | $6.30 | |||
| Enterprise Value/EBITDA (TTM) | -15.63 | |||
| Enterprise Value/EBIT | -15.41 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 61.51M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 908 517 9500 | |||
| Address | 300 Connell Drive Berkeley Heights, NJ 07922 | |||
| Website | www.cormedix.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -51.42% | |||
| Profit Margin | -41.24% | |||
| Management Effectiveness | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -13.91% | |||
| Return on Equity | -- | |||
| Income Statement | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 43.47M | |||
| Total Revenue (TTM) | 43.47M | |||
| Revenue Per Share | $0.71 | |||
| Gross Profit (TTM) | 40.28M | |||
| EBITDA (TTM) | -22.05M | |||
| EBIT (TTM) | -22.36M | |||
| Net Income (TTM) | -17.93M | |||
| Net Income Avl. to Common (TTM) | -17.93M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 191.26% | |||
| EPS Diluted (TTM) | -0.33 | |||
| EPS Diluted Growth (Q YOY) | 185.14% | |||
| Balance Sheet | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 51.69M | |||
| Cash Per Share (Q) | $0.84 | |||
| Total Current Assets (Q) | 114.58M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 84.66M | |||
| Current Ratio (Q) | 3.386 | |||
| Book Value Per Share (Q) | $1.31 | |||
| Total Assets (Q) | 118.85M | |||
| Total Current Liabilities (Q) | 33.84M | |||
| Total Debt (Q) | 517.00K | |||
| Total Liabilities (Q) | 34.19M | |||
| Total Common Equity (Q) | 84.66M | |||
| Cash Flow | CRMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 21.23M | |||
| Cash from Financing (TTM) | 26.32M | |||
| Net Change in Cash (TTM) | -3.07M | |||
| Levered Free Cash Flow (TTM) | -44.94M | |||
| Cash from Operations (TTM) | -50.61M | |||
